Busey Trust CO Purchases 11,715 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Busey Trust CO boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 67,959 shares of the biopharmaceutical company’s stock after buying an additional 11,715 shares during the period. Busey Trust CO’s holdings in Gilead Sciences were worth $4,616,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Hall Laurie J Trustee boosted its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC boosted its position in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the last quarter. Dubuque Bank & Trust Co. boosted its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the last quarter. Webster Bank N. A. boosted its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares during the last quarter. Finally, Thomas J. Herzfeld Advisors Inc. bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $143,000. Hedge funds and other institutional investors own 74.03% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 71.15 on Tuesday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $88.85. The company’s 50-day moving average price is $66.03 and its 200 day moving average price is $68.95. The company has a market cap of $92.97 billion, a P/E ratio of 7.52 and a beta of 1.20.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.66 billion. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.37 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Friday, June 16th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date was Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.

COPYRIGHT VIOLATION NOTICE: “Busey Trust CO Purchases 11,715 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/07/18/busey-trust-co-purchases-11715-shares-of-gilead-sciences-inc-nasdaqgild.html.

Several analysts recently weighed in on GILD shares. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research note on Monday. Robert W. Baird reaffirmed an “outperform” rating and issued a $87.00 price objective on shares of Gilead Sciences in a research note on Thursday, July 13th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a research note on Tuesday, July 11th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 11th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a research note on Wednesday, July 5th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $80.24.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,276 shares of company stock valued at $6,230,610. 1.30% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply